# MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

> **NCT04495621** · PHASE1,PHASE2 · COMPLETED · sponsor: **Menarini Group** · enrollment: 29 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** MEN1611
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT04495621
- **Lead sponsor:** Menarini Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-20
- **Primary completion:** 2024-01-12
- **Final completion:** 2024-02-27
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04495621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04495621, "MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04495621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*